Oxford Immunotec Global PLC (OXFD) Getting Somewhat Positive Media Coverage, Study Shows

News stories about Oxford Immunotec Global PLC (NASDAQ:OXFD) have been trending somewhat positive this week, AlphaOne reports. The research firm, a division of Accern, rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford Immunotec Global PLC earned a news sentiment score of 0.04 on AlphaOne’s scale. AlphaOne also gave news coverage about the company an impact score of 63 out of 100, meaning that recent press coverage is somewhat likely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted AlphaOne Sentiment’s rankings:

Several equities research analysts have issued reports on OXFD shares. Zacks Investment Research upgraded shares of Oxford Immunotec Global PLC from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research report on Thursday, March 9th. BTIG Research restated a “buy” rating and set a $19.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Friday, March 10th.

Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 0.13% during midday trading on Friday, hitting $15.48. 60,932 shares of the stock were exchanged. Oxford Immunotec Global PLC has a 1-year low of $7.73 and a 1-year high of $16.13. The firm’s market capitalization is $351.58 million. The firm’s 50-day moving average price is $15.30 and its 200 day moving average price is $14.27.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its quarterly earnings results on Wednesday, March 1st. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.17. The company had revenue of $23.71 million for the quarter, compared to the consensus estimate of $23.06 million. Oxford Immunotec Global PLC had a negative net margin of 30.17% and a negative return on equity of 28.36%. Oxford Immunotec Global PLC’s revenue was up 41.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. Analysts expect that Oxford Immunotec Global PLC will post ($1.03) earnings per share for the current fiscal year.

In other news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $15.47, for a total value of $46,410.00. Following the transaction, the director now directly owns 17,174 shares in the company, valued at $265,681.78. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Peter Wrighton-Smith sold 30,000 shares of the company’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $15.43, for a total transaction of $462,900.00. Following the completion of the transaction, the chief executive officer now owns 491,668 shares in the company, valued at $7,586,437.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,000 shares of company stock worth $891,460. 7.58% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This report was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/04/21/oxford-immunotec-global-plc-oxfd-earning-somewhat-positive-news-coverage-study-finds-updated.html.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

5 Day Chart for NASDAQ:OXFD

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply